PMC:7574920 / 36311-37004
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T143 | 39-42 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
| T144 | 157-160 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T83 | 292-300 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T310 | 230-232 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
| T311 | 314-318 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
| T312 | 364-365 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T313 | 538-540 | http://purl.obolibrary.org/obo/CLO_0001302 | denotes | 34 |
| T314 | 545-546 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T315 | 577-579 | http://purl.obolibrary.org/obo/CLO_0001313 | denotes | 36 |
| T316 | 639-645 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T71 | 474-489 | Chemical | denotes | oligonucleotide | http://purl.obolibrary.org/obo/CHEBI_7754 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 252 | 292-302 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 253 | 474-489 | Chemical | denotes | oligonucleotide | MESH:D009841 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T271 | 0-204 | Sentence | denotes | Although spike-in experiments with IVT RNA can be informative, we have experienced clear differences when comparing such experiments to those using clinical RNA samples isolated from swab specimens (figs. |
| T272 | 205-234 | Sentence | denotes | S6 and S7, and data file S1). |
| T273 | 235-410 | Sentence | denotes | We therefore recommend validating any new proposed rapid SARS-CoV-2 diagnostic test using “real-life” clinical samples including a large fraction of negative clinical samples. |
| T274 | 411-595 | Sentence | denotes | To overcome the problem of spurious amplification, an expanded oligonucleotide set that incorporates sequence-specific probes (34) or a CRISPR/Cas12a–based approach (36) could be used. |
| T275 | 596-693 | Sentence | denotes | However, these applications have yet to be tested with large numbers of diverse clinical samples. |